Related Experiment Videos
Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia
Insights
Low-dose aspirin (40 mg) effectively inhibits platelet aggregation and thromboxane A2 synthesis in patients with recent cerebral ischemia. This cumulative antiplatelet effect is comparable to higher aspirin doses.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Occlusive cerebrovascular disease poses significant risks.
- Conventional aspirin doses inhibit both platelet function and vascular prostacyclin synthesis.
- Understanding low-dose aspirin's specific antiplatelet effects is crucial for managing cerebrovascular events.
Purpose of the Study:
- To evaluate the antiplatelet efficacy of low-dose aspirin (40 mg daily) in patients with occlusive cerebrovascular disease.
- To compare the effects of low-dose aspirin alone versus aspirin plus dipyridamole on platelet function.
- To assess the impact of low-dose aspirin on thromboxane A2 synthesis.
Main Methods:
- 23 patients with recent cerebral ischemia were treated with 40 mg aspirin daily or aspirin plus dipyridamole.
- Platelet aggregation responses to arachidonate, epinephrine, adenosine diphosphate, and collagen were measured.
- Serum thromboxane B2 levels were quantified to assess thromboxane A2 synthesis.
Main Results:
- Low-dose aspirin (40 mg) significantly suppressed platelet aggregation within 3-7 days.
- Serotonin release and thromboxane B2 levels decreased by over 95%.
- Similar antiplatelet effects were observed regardless of aspirin combination, sex, or specific cerebrovascular event (TIA vs. stroke).
Conclusions:
- 40 mg of aspirin daily provides potent antiplatelet effects in patients with recent cerebral ischemia.
- Low-dose aspirin is as effective as higher doses in inhibiting platelet function and thromboxane A2 synthesis.
- This study demonstrates a cumulative antiplatelet effect of low-dose aspirin in this patient population.
Abstract:
We tested the antiplatelet effects of low-dose aspirin in patients with occlusive cerebrovascular disease, because conventional dosage aspirin inhibits vascular synthesis of prostacyclin at the same time that it inhibits platelets. The effects on platelet function and thromboxane A2 synthesis of 40 mg of aspirin daily or 40 mg aspirin plus dipyridamole were measured in 23 patients starting within a week after the onset of cerebral ischemia. All patients had normal baseline platelet aggregation responses to four stimuli: arachidonate, epinephrine, adenosine diphosphate and collagen. The generation of thromboxane A2 by platelets, measured as serum thromboxane B2, was also normal. After 3 to 7 days of low dose aspirin therapy, platelet aggregation responses were suppressed to the extent observed with higher dosage aspirin. Serotonin release during platelet aggregation was inhibited by more than 95% and thromboxane B2 levels in clotted blood fell by more than 95%. Responses to aspirin treatment were similar in patients with transient ischemic attacks and in those with stroke and were also similar in both sexes. No differences in platelet responses were observed between patients receiving aspirin alone and aspirin plus dipyridamole. Thus 40 mg aspirin daily inhibited platelet responses as effectively as higher doses of aspirin in patients who had recent cerebral ischemia and showed a cumulative antiplatelet effect.